Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset 9)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2018
At a glance
- Drugs Insulin aspart (Primary) ; Insulin degludec (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms onset9
- Sponsors Novo Nordisk
- 24 Oct 2018 This trial has been completed in Germany.
- 31 Aug 2018 Biomarkers information updated
- 10 Jul 2018 Status changed from recruiting to active, no longer recruiting.